News | September 08, 2014

MedStar Georgetown to Install Mevion S250 Proton Therapy System to Treat Adult and Pediatric Cancer Patients

MedStar Georgetown University Hospital to bring first proton therapy center to Washington, D.C.

September 8, 2014 — Mevion Medical Systems announced that MedStar Georgetown University Hospital has received final approval to begin construction of the first proton therapy center in Washington, D.C., at its Lombardi Comprehensive Cancer Center.

Georgetown Lombardi is the only cancer center in the D.C. area to earn the National Cancer Institute (NCI) designation as a comprehensive cancer center. The Mevion S250, the world’s smallest single-room proton therapy system, delivers the same precise, noninvasive treatment advantages and capabilities of larger, more expensive proton therapy systems but with a significantly reduced footprint, improved reliability, more efficient patient access, and dramatically lower implementation and operational costs.

Proton therapy is an advanced form of external radiation treatment that aims a powerful beam of protons at a tumor with incredible accuracy. Because of the special properties of protons, treatments result in less damage to surrounding healthy tissue and a reduced risk of secondary malignancies. Proton therapy is commonly used to treat a wide range of cancers in sensitive locations, such as the central nervous system, chest, head and neck, eye, and prostate. This advanced form of radiation is extremely valuable for the treatment of cancer in pediatric patients, who can be more prone to complications from radiation treatment.

Construction is scheduled to start in the fall, with installation of the Mevion S250 to be complete in 2016.

“The addition of proton therapy to our experienced and internationally known cancer program is a natural progression for us as the only provider in the region with a long history of serving both children as well as adults with cancer,” said Richard Goldberg, M.D., president, MedStar Georgetown University Hospital. “We are excited to bring this important technology to our community and to give our patients yet another cutting-edge cancer treatment option.”

“The Mevion S250 proton therapy system provides a significant benefit to cancer patients while redefining the economics and accessibility of proton therapy,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems. “We are proud to bring the most advanced radiation therapy device to our nation’s capital and another leading healthcare institution.”

For more information:,

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init